Alkermes (ALKS) is lower in Wednesday trading (May 6, 2026) as the market digests the company’s first-quarter 2026 earnings released May 5, which showed a swing to a GAAP net loss of $66.5 million (-$0.40 per share) on revenue of $392.9 million. The pullback follows an initial read-through that emphasized strong revenue growth, with the stock now reacting to the profitability profile and acquisition-related noise embedded in the results. (stocktitan.net)

In the quarter, Alkermes posted total revenue of $392.9 million, while reporting a GAAP net loss of $66.5 million. Management framed the period as a strong operational quarter and highlighted strategic progress in sleep medicine after completing the Avadel Pharmaceuticals acquisition in February 2026, but the GAAP loss headline is still a focal point for investors recalibrating expectations following the deal. (stocktitan.net)

A key driver of today’s move is investor positioning around how acquisition accounting and transaction-related items affect near-term reported earnings. Alkermes said it updated certain non-cash elements of its 2026 full-year financial expectations connected to purchase price accounting for Avadel, which can improve some GAAP metrics even as it introduces new moving pieces (including inventory and intangible-related effects) that can cloud underlying run-rate profitability. (stocktitan.net)

Investors will likely monitor whether the market’s attention shifts from top-line momentum to the cadence of profit normalization as Avadel is integrated, including how the newly acquired sleep franchise contributes across a full quarter and how management’s updated 2026 framework is interpreted versus prior expectations. Near-term trading may remain sensitive to incremental analyst target changes and to any added detail that emerges in filings and follow-on commentary around the acquisition’s accounting impacts. (stocktitan.net)